233 related articles for article (PubMed ID: 12835613)
1. Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects?
Bramness JG; Skurtveit S; Fauske L; Grung M; Molven A; Mørland J; Steen VM
Pharmacogenetics; 2003 Jul; 13(7):383-8. PubMed ID: 12835613
[TBL] [Abstract][Full Text] [Related]
2. CYP2C19 genetics in fatal carisoprodol intoxications.
Høiseth G; Majid U; Mørland J; Bramness JG; Molden E
Eur J Clin Pharmacol; 2012 Nov; 68(11):1561-5. PubMed ID: 22527345
[TBL] [Abstract][Full Text] [Related]
3. Formation of meprobamate from carisoprodol is catalysed by CYP2C19.
Dalén P; Alvan G; Wakelkamp M; Olsen H
Pharmacogenetics; 1996 Oct; 6(5):387-94. PubMed ID: 8946470
[TBL] [Abstract][Full Text] [Related]
4. The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects.
Bramness JG; Skurtveit S; Gulliksen M; Breilid H; Steen VM; Mørland J
Eur J Clin Pharmacol; 2005 Aug; 61(7):499-506. PubMed ID: 16021435
[TBL] [Abstract][Full Text] [Related]
5. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele.
Xiao ZS; Goldstein JA; Xie HG; Blaisdell J; Wang W; Jiang CH; Yan FX; He N; Huang SL; Xu ZH; Zhou HH
J Pharmacol Exp Ther; 1997 Apr; 281(1):604-9. PubMed ID: 9103550
[TBL] [Abstract][Full Text] [Related]
6. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.
Persson I; Aklillu E; Rodrigues F; Bertilsson L; Ingelman-Sundberg M
Pharmacogenetics; 1996 Dec; 6(6):521-6. PubMed ID: 9014201
[TBL] [Abstract][Full Text] [Related]
7. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population.
Sviri S; Shpizen S; Leitersdorf E; Levy M; Caraco Y
Clin Pharmacol Ther; 1999 Mar; 65(3):275-82. PubMed ID: 10096259
[TBL] [Abstract][Full Text] [Related]
9. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.
Sim SC; Risinger C; Dahl ML; Aklillu E; Christensen M; Bertilsson L; Ingelman-Sundberg M
Clin Pharmacol Ther; 2006 Jan; 79(1):103-13. PubMed ID: 16413245
[TBL] [Abstract][Full Text] [Related]
10. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study.
Luo HR; Poland RE; Lin KM; Wan YJ
Clin Pharmacol Ther; 2006 Jul; 80(1):33-40. PubMed ID: 16815315
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting carisoprodol metabolism in pain patients using urinary excretion data.
Tse SA; Atayee RS; Ma JD; Best BM
J Anal Toxicol; 2014 Apr; 38(3):122-8. PubMed ID: 24488112
[TBL] [Abstract][Full Text] [Related]
13. In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease.
Ohnishi A; Murakami S; Akizuki S; Mochizuki J; Echizen H; Takagi I
J Clin Pharmacol; 2005 Nov; 45(11):1221-9. PubMed ID: 16239354
[TBL] [Abstract][Full Text] [Related]
14. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.
Brøsen K; de Morais SM; Meyer UA; Goldstein JA
Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772
[TBL] [Abstract][Full Text] [Related]
15. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations.
Kaneko A; Bergqvist Y; Taleo G; Kobayakawa T; Ishizaki T; Björkman A
Pharmacogenetics; 1999 Jun; 9(3):317-26. PubMed ID: 10471063
[TBL] [Abstract][Full Text] [Related]
16. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam.
Kosaki K; Tamura K; Sato R; Samejima H; Tanigawara Y; Takahashi T
Brain Dev; 2004 Dec; 26(8):530-4. PubMed ID: 15533655
[TBL] [Abstract][Full Text] [Related]
17. The influence of St John's Wort on CYP2C19 activity with respect to genotype.
Wang LS; Zhu B; Abd El-Aty AM; Zhou G; Li Z; Wu J; Chen GL; Liu J; Tang ZR; An W; Li Q; Wang D; Zhou HH
J Clin Pharmacol; 2004 Jun; 44(6):577-81. PubMed ID: 15145964
[TBL] [Abstract][Full Text] [Related]
18. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.
van der Weide J; van Baalen-Benedek EH; Kootstra-Ros JE
Ther Drug Monit; 2005 Aug; 27(4):478-83. PubMed ID: 16044105
[TBL] [Abstract][Full Text] [Related]
19. CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase.
Zhou HH
Clin Chim Acta; 2001 Nov; 313(1-2):203-8. PubMed ID: 11694260
[TBL] [Abstract][Full Text] [Related]
20. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
